Table S3. Number of screen-detected cases, expected number of detected non-progressive in situ combined with invasive breast cancers (non-progressive breast cancer, or NPBC), and the frequency of overdiagnosis (percentage) by round of screening. (DOCX 13 kb
Table S1. Linear regression coefficients for association between the tumor size (mm) and selected pa...
Table S1. For interval and screen-detected invasive breast cancer, marginal risk estimates for Cumul...
Table S1. Pathological analysis of benign breast lesions within our HMD and LMD cohort. Those patien...
Table S1. Number of person-years, in situ and invasive breast cancer cases by detection mode, interv...
Table S2. Maximum-likelihood estimates (MLEs) and 95% confidence intervals (CIs) based on the non-ho...
Selected chronic disease groups and the included diseases in each group together with their ICD-10 c...
Table S1. Stage distribution by diagnosis mode among Volpara density grade categories. Table S2. Bio...
Table S1. Overdiagnosis frames used by experts (organised according to main professional role). Tabl...
Background: Overdiagnosis, defined as the detection of a cancer that would not become clinically app...
Table S1. The specifications and codes for the indicator variables. Table S2. The validity results o...
Projection of internal TNBC cohorts in the first PCA plane. (A) PACS08 patients (n = 131, [orange]) ...
Subgroup analysis - Recall rate of DBT and DM in screening studies using two study groups by outcome...
Associations of extent of mammographic breast density with breast cancer risk in women with atypical...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Figure S4. (A) Survival analyses (time to systemic relapse/breast cancer death) in relation to NR2F1...
Table S1. Linear regression coefficients for association between the tumor size (mm) and selected pa...
Table S1. For interval and screen-detected invasive breast cancer, marginal risk estimates for Cumul...
Table S1. Pathological analysis of benign breast lesions within our HMD and LMD cohort. Those patien...
Table S1. Number of person-years, in situ and invasive breast cancer cases by detection mode, interv...
Table S2. Maximum-likelihood estimates (MLEs) and 95% confidence intervals (CIs) based on the non-ho...
Selected chronic disease groups and the included diseases in each group together with their ICD-10 c...
Table S1. Stage distribution by diagnosis mode among Volpara density grade categories. Table S2. Bio...
Table S1. Overdiagnosis frames used by experts (organised according to main professional role). Tabl...
Background: Overdiagnosis, defined as the detection of a cancer that would not become clinically app...
Table S1. The specifications and codes for the indicator variables. Table S2. The validity results o...
Projection of internal TNBC cohorts in the first PCA plane. (A) PACS08 patients (n = 131, [orange]) ...
Subgroup analysis - Recall rate of DBT and DM in screening studies using two study groups by outcome...
Associations of extent of mammographic breast density with breast cancer risk in women with atypical...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Figure S4. (A) Survival analyses (time to systemic relapse/breast cancer death) in relation to NR2F1...
Table S1. Linear regression coefficients for association between the tumor size (mm) and selected pa...
Table S1. For interval and screen-detected invasive breast cancer, marginal risk estimates for Cumul...
Table S1. Pathological analysis of benign breast lesions within our HMD and LMD cohort. Those patien...